Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportGeneral Clinical Specialties: General Practice: Oncology

Role of 18F-FDG PET-CT in prediction of survival in recurrent glioma patients

Amburanjan Santra, Rakesh Kumar, Chandrasekhar Bal, Pramod Julka and A. Malhotra
Journal of Nuclear Medicine May 2009, 50 (supplement 2) 1333;
Amburanjan Santra
1All India Institute of Medical Sciences, Department of Nuclear Medicine, New Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rakesh Kumar
1All India Institute of Medical Sciences, Department of Nuclear Medicine, New Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chandrasekhar Bal
1All India Institute of Medical Sciences, Department of Nuclear Medicine, New Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pramod Julka
1All India Institute of Medical Sciences, Department of Nuclear Medicine, New Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Malhotra
1All India Institute of Medical Sciences, Department of Nuclear Medicine, New Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1333

Objectives Purpose of this study was to evaluate the role of 18F-FDG PET-CT in prediction of survival in recurrent glioma patients.

Methods Eighty patients with clinical suspicion of recurrent glioma underwent FDG PET-CT scan. In all positive cases, tumor to gray mater (T/G) and tumor to white mater (T/W) uptake ratio calculated. Patients were followed up clinically with (Temozolamide in 32, reoperation in 5, radiotherapy in 2) or without treatment (41). Univariate and multivariate analyses were done to see the association of survival with different factors like age, sex, size and grade, previous treatment, clinical symptoms, treatment for recurrence, T/G and T/W ratios. Kaplan Meier survival estimates were done using FDG PET-CT findings.

Results FDG PET/CT scan was positive in 43 while negative in 37 patients. 17 FDG positive and 2 FDG negative patients were died in median follow up period of 342 days (12days -783 days). In univriate analysis, significant association was found with size, T/G ratio, T/W ratio, pretreatment and treatment of recurrence. In multivariate analysis, T/G ratio(p=0.000), T/W ratio(p=0.023) and treatment of recurrence with Temozolamide (p=0.002) had only significance. In Kaplan Meier estimates, FDG positive patients had poorer prognosis than negative patients(p=0.001) and T/G >1had poorer prognosis than T/G <1(p=0.000).

Conclusions FDG PET/CT is a strong predictor of survival in the patients of recurrent glioma. Both the uptake ratios (T/G and T/W) are independent predictor, but strongest association found with T/G ratio.

  • © 2009 by Society of Nuclear Medicine
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 50, Issue supplement 2
May 2009
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Role of 18F-FDG PET-CT in prediction of survival in recurrent glioma patients
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Role of 18F-FDG PET-CT in prediction of survival in recurrent glioma patients
Amburanjan Santra, Rakesh Kumar, Chandrasekhar Bal, Pramod Julka, A. Malhotra
Journal of Nuclear Medicine May 2009, 50 (supplement 2) 1333;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Role of 18F-FDG PET-CT in prediction of survival in recurrent glioma patients
Amburanjan Santra, Rakesh Kumar, Chandrasekhar Bal, Pramod Julka, A. Malhotra
Journal of Nuclear Medicine May 2009, 50 (supplement 2) 1333;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

General Clinical Specialties: General Practice: Oncology

  • Differentiated thyroid carcinoma (DTC) follow up: A 131I-SPECT/CT study
  • Determination of metabolic tumor response by FDG PET is highly reproducible with the same or different readers pre- and post-therapy
  • Role of FDG-PET/CT in cases of incidentally detected raised serum CEA with no known malignancy: Experience in a tertiary care referral center
Show more General Clinical Specialties: General Practice: Oncology

General Practice-Oncology Posters

  • Limited added value of delayed FDG PET images in the differential diagnosis of pulmonary lesions in a cohort with a high prevalence of active inflammations
  • Survival rate (SR) in patients (pts) diagnosed (dx’ed) with well-differentiated thyroid cancer (WDTC) with bone metastases (BMs)
  • Metabolic characterization of untreated lung adenocarcinoma with 18F-FDG PET/CT: Impact of smoking
Show more General Practice-Oncology Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire